Skip to content

Study · Non-randomized trial · n = 4 · 1998

13 results

Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance).

Laron Z, Klinger B

European journal of endocrinology1 Feb 1998Cited by 66 (Europe PMC)

PMID9506862 (opens in a new tab)DOI10.1530/eje.0.1380176 (opens in a new tab)PepBankPUB-09506862
Source linkPubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In very young boys with Laron syndrome, IGF-I did not change serum gonadotrophins.

    In plain wordsIn very young boys with Laron syndrome, IGF-I did not change gonadotrophin levels.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeGonadotrophins in very young boys
    Study

    n = 4

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    150 microg/kg per day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the very young boys no change in serum gonadotrophins, androgens, gonads or genitals was registered.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  2. 02HumanNon-randomized trialEfficacy outcome

    In very young boys with Laron syndrome, IGF-I did not change serum androgens.

    In plain wordsIn very young boys with Laron syndrome, IGF-I did not change androgen levels.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeAndrogens in very young boys
    Study

    n = 4

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    150 microg/kg per day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the very young boys no change in serum gonadotrophins, androgens, gonads or genitals was registered.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  3. 03HumanNon-randomized trialEfficacy outcome

    In very young boys with Laron syndrome, IGF-I did not change gonads.

    In plain wordsIn very young boys with Laron syndrome, IGF-I did not change the gonads.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeGonads in very young boys
    Study

    n = 4

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    150 microg/kg per day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the very young boys no change in serum gonadotrophins, androgens, gonads or genitals was registered.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  4. 04HumanNon-randomized trialEfficacy outcome

    In very young boys with Laron syndrome, IGF-I did not change genitals.

    In plain wordsIn very young boys with Laron syndrome, IGF-I did not change the genitals.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeGenitals in very young boys
    Study

    n = 4

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    150 microg/kg per day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the very young boys no change in serum gonadotrophins, androgens, gonads or genitals was registered.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  5. 05HumanNon-randomized trialEfficacy outcome

    In older boys and an adult with Laron syndrome, luteinizing hormone rose progressively during IGF-I treatment.

    In plain wordsIn older boys and an adult with Laron syndrome, luteinizing hormone rose during IGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseLuteinizing hormone
    Study

    n = 3

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient, once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the two older boys and the adult patient, there was a progressive rise in luteinizing hormone, follicle-stimulating hormone and testosterone.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  6. 06HumanNon-randomized trialEfficacy outcome

    In older boys and an adult with Laron syndrome, follicle-stimulating hormone rose progressively during IGF-I treatment.

    In plain wordsIn older boys and an adult with Laron syndrome, follicle-stimulating hormone rose during IGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseFollicle-stimulating hormone
    Study

    n = 3

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient, once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the two older boys and the adult patient, there was a progressive rise in luteinizing hormone, follicle-stimulating hormone and testosterone.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  7. 07HumanNon-randomized trialEfficacy outcome

    In older boys and an adult with Laron syndrome, testosterone rose progressively during IGF-I treatment.

    In plain wordsIn older boys and an adult with Laron syndrome, testosterone rose during IGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseTestosterone
    Study

    n = 3

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient, once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the two older boys and the adult patient, there was a progressive rise in luteinizing hormone, follicle-stimulating hormone and testosterone.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  8. 08HumanNon-randomized trialEfficacy outcome

    In older boys and an adult with Laron syndrome, testicular size increased during IGF-I treatment.

    In plain wordsIn older boys and an adult with Laron syndrome, the testes increased in size during IGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseTesticular size
    Study

    n = 3

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient, once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Concomitantly, there was an increase in size of the testes and penile length.
    4 context sentences
    Summary · context
    In the two older boys and the adult patient, there was a progressive rise in luteinizing hormone, follicle-stimulating hormone and testosterone.
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  9. 09HumanNon-randomized trialEfficacy outcome

    In older boys and an adult with Laron syndrome, penile length increased during IGF-I treatment.

    In plain wordsIn older boys and an adult with Laron syndrome, penile length increased during IGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreasePenile length
    Study

    n = 3

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient, once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Concomitantly, there was an increase in size of the testes and penile length.
    4 context sentences
    Summary · context
    In the two older boys and the adult patient, there was a progressive rise in luteinizing hormone, follicle-stimulating hormone and testosterone.
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  10. 10HumanNon-randomized trialEfficacy outcome

    In the older boys with Laron syndrome, puberty started during IGF-I treatment.

    In plain wordsIn the older boys with Laron syndrome, puberty started during IGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    Not applicablePuberty onset
    Study

    n = 2

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    150 microg/kg per day · subcutaneousAs given in this study (human).

    Measurements

    Boys who started puberty
    2 boys
    Older boys with Laron syndrome during IGF-I treatment

    Source sentences

    Summary
    The two boys started puberty.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  11. 11HumanNon-randomized trialEfficacy outcome

    In the adult with Laron syndrome, very high serum IGF-I prompted progressive dose reduction.

    In plain wordsIn the adult with Laron syndrome, very high blood IGF-I led to a reduced dose.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    Not applicableAdult serum IGF-I
    Study

    n = 1

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    120 microg/kg per day, progressively decreased to 70 microg/kg per day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    As very high serum IGF-I levels were registered in the adult patient, the daily dose was progressively decreased to 70 microg/kg per day.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  12. 12HumanNon-randomized trialEfficacy outcome

    In the adult with Laron syndrome, stopping IGF-I returned testicular size to pretreatment size.

    In plain wordsIn the adult with Laron syndrome, stopping IGF-I returned testicular size to its pretreatment value.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseTesticular size after cessation
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Stopping the IGF-I administration in this patient, according to the protocol, led to a return to pretreatment serum levels and testicular and penile size.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.
  13. 13HumanNon-randomized trialEfficacy outcome

    In the adult with Laron syndrome, stopping IGF-I returned penile size to pretreatment size.

    In plain wordsIn the adult with Laron syndrome, stopping IGF-I returned penile size to its pretreatment value.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreasePenile size after cessation
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Stopping the IGF-I administration in this patient, according to the protocol, led to a return to pretreatment serum levels and testicular and penile size.
    3 context sentences
    Summary · context
    Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size.
    Summary · context
    The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult.
    Summary · context
    IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.